Bioorg. Med. Chem. Lett. 2023, 93, 129412
DOI: 10.1016/j.bmcl.2023.129412
Detta E.; Corcuera A.; Urban A.; Goldner T.; Bonsmann S.; Engel F.; May M.; Buschmann H.; Fianchini M.; Alza E.; Pericas M. et al.
Small-molecule capsid assembly modulators (CAMs) have been recently recognized as promising antiviral agents for curing chronic hepatitis B virus (HBV) infection. A target-based in silico screening study is described, aimed towards the discovery of novel HBV CAMs. Initial optimization of four weakly active screening hits was performed via focused library synthesis. Lead compound 42 and close analogues 56 and 57 exhibited in vitro potency in the sub- and micromolar range along with good physico-chemical properties and were further evaluated in molecular docking and mechanism of action studies.